Heat Biologics Inc. (HTBX) Stock
HTBX is no longer traded. Heat Biologics was delisted from the NYSE in June 2022.
Prices on this page are historical; the last trade was June 30, 2022 at $2.55.
Heat Biologics stock price history
HTBX final trading statistics
- Final close
- $2.55
- Final trading day
- Jun 30, 2022
- Market cap at delisting
- $65.41M
- Shares outstanding
- 25.65M
- Final 52-week range
- $1.60 – $7.63
- Avg. volume (final 3 mo.)
- 105,905
- All-time high (split-adj.)
- $71540.00 · Oct 2013
- All-time low (split-adj.)
- $1.49 · Feb 2020
- Return since IPO
- -100.0%
- Beta
- 0.30
- Book value / share
- $4.41
- Price / book
- 0.58
Heat Biologics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $2.11M | -$35.4M | -$1.41 |
| FY2020 | $2.95M | -$26.0M | -$1.56 |
| FY2019 | $3.05M | -$20.0M | -$3.71 |
| FY2018 | $5.79M | -$15.7M | -$6.73 |
| FY2017 | $1.52M | -$11.8M | -$3.08 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Heat Biologics Inc.
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Heat Biologics stock FAQ
What happened to Heat Biologics stock?
Heat Biologics stock was delisted from the NYSE. Its final close was $2.55 on June 30, 2022.
Is HTBX stock still trading?
No. HTBX was delisted from the NYSE in June 2022 and no longer trades on a U.S. exchange.
What was the last price of HTBX stock?
HTBX closed at $2.55 on its final trading day, June 30, 2022, for a market value of about $65.41M.
What were Heat Biologics's revenue and earnings in its last full fiscal year?
Heat Biologics reported revenue of $2.11M and net income of -$35.4M in fiscal 2021, its last full year as a public company.
When did Heat Biologics go public?
Heat Biologics Inc. stock began trading on July 24, 2013.